Welcome to “Stock of the Week”, a recurring series focused on companies experiencing meaningful news flow or changes in their investment case. The objective is not to react to headlines but to understand what is happening beneath the surface and whether recent developments materially affect the long-term investment thesis.
Each article applies the Quality Stocks Investment Framework to assess business quality, return potential and execution, in order to determine whether the stock is Attractive, Conditional, or Unattractive at the current price. A standardized one-pager accompanies each edition to make the decision process clear and easy to follow.
For paid subscribers, Stock of the Week goes a step further by opening up the full reasoning behind the investment thesis and decision process:
Detailed TSR calculations, including all underlying assumptions. This allows investors to understand what must go right for the investment to deliver acceptable returns and to stress-test their own expectations against explicit inputs
My analysis beyond the overall verdict. This provides a deeper insight, enabling investors to form an independent view rather than relying solely on a conclusion
This week’s spotlight is on UnitedHealth. Following a brutal 2025 that saw the stock plummet over 60% amidst a margin collapse that actually took root in 2024, shares have staged a significant recovery, clawing back roughly half of those losses. Yet, despite these recent signs of operational life, the company's fundamentals remain a shadow of their historical benchmarks. This begs the question: is this a genuine structural turnaround or simply a temporary relief rally? Let’s dive into the data.
Missed an edition? Catch up on our recent analyses
One Pager
The stock at a glance
Want to understand how the Quality Stocks Investment Framework works? This article breaks it down for you
Data for this week’s analysis was sourced via MarketScreener. It is my go-to platform for global stock data and analyst price targets. If you are looking to upgrade your research toolkit, click here (Full disclosure: this is an affiliate link, so you will be supporting this newsletter at no extra cost to you!)
Recent news
The company reported strong Q1 results with total revenue reaching $111.7B and an adjusted EPS of $7.23, beating Wall Street expectations and prompting management to raise its FY guidance to more than $18.25 EPS
Operating margins staged a sharp sequential recovery to 8% following a steep contraction below 1% in late 2025, fueled by aggressive cost-reduction efforts and the deployment of generative artificial intelligence across core operations
The Board of Directors authorized a 5% increase to its quarterly cash dividend, raising it to $2.32 per share
UnitedHealth is actively planning a strategic reduction of its Medicare Advantage membership by 2 to 3M individuals in response to tightening regulatory scrutiny, compliance findings on claim denials and lower federal reimbursement rates
Large institutional funds, including Berkshire Hathaway and Appaloosa Management, have recently trimmed or completely exited their equity positions in the company amid the shifting dynamics of the government insurance book
The insurance segment has significantly rolled back its administrative requirements for care providers, eliminating nearly two-thirds of prior authorizations for pediatric services and executing a 30% reduction across its broader network
Maryland regulatory authorities approved a modified midyear premium rate hike for the small-business market effective October 1, allowing a 1.5% adjustment to combat rising hospital and specialty drug costs instead of the 17.6% increase initially requested
Wall Street sentiment heading into the upcoming second-quarter earnings release remains constructive
Recent analyst recommendation updates
June, 24. Bank of America. Buy. $450 —> $475
June, 17. Leerink Partners. Buy. $400 —> $462
June, 08. JP Morgan. Buy. $420 —> $466
To go beyond the initial assessment, paid subscribers unlock the detailed TSR calculation with underlying assumptions and my analysis of the situation, providing deeper insight into how recent developments affect risks, opportunities and the overall verdict
